Access To Medicine Foundation

Often searched

Index ranking

Vacancies

10 year analysis

  • Healthcare inequity
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
  • Become a catalyst
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
  • Sectors and research
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Research hub
    • Company profiles & report cards
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Research hub
    • Company profiles & report cards
  • Cross-Sector Programmes
    • Antimicrobial resistance
    • Diabetes care
    • Antimicrobial resistance
    • Diabetes care
  • On the pulse of global health
    • Access insights
    • Health Equity through Her Lens
    • The Health Equity podcast
    • Access insights
    • Health Equity through Her Lens
    • The Health Equity podcast
  • News
  • Our team
  • Featured insights
  • Governance & financials
  • Vacancies
  • Media coverage
  • FAQ
  • Contact us

Date

28 September 2023

Generic drugs still out of reach despite effort to ensure access

Kenya's The Star writes about the launch of the Access to Medicine Foundation's first report from its Generic & Biosimilar Medicine Programme. The report profiles five major generic companies: Cipla, Hikma, Sun Pharma, Teva and Viatris. Each of the companies is assessed on their efforts to expand access to their products in low- and middle-income countries.

Direct links

Read the article

The article notes that many patients in low- and middle-income countries, including Kenya, still lack access to essential medicines, despite efforts to make them available.

One of the key findings from the report is also highlighted; even if a generic product is comparatively cheaper, patients who have to pay out-of-pocket may still not be able to afford it.

Read the Foundation's report on generic and biosimilar medicine manufacturers.

Access to Medicine Foundation

Interested in our work?

Access to Medicine Foundation is funded by

Terms & conditions

Privacy & cookie policy

Disclaimer

Copyright 2004 - 2025 Access to Medicine Foundation - All Rights Reserved